Monopar Therapeutics furthers camsirubicin trial past 4th cohort for ASTS

Monopar Therapeutics announced the positive recommendation from its safety review committee to advance to the fifth dose level in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma ASTS . This decision was made following a review of safety data from the patients in the first four dose cohorts." Clearance to go to this higher dose level is an important milestone for the trial as this class of drugs is known to have dose-dependent anti-tumor activity," said Chandler Robinson, MD, Monopar’s Chief Executive Officer. "We continue to see a favorable safety profile compared to doxorubicin, and the Phase 1b data to-date shows an improvement in median progression free survival from what was observed in the prior camsirubicin Phase 2 trial, 265mg/m2 . We are looking forward to evaluating the 650 mg/m2 dose level, which is nearly 2.5x higher than the highest dose evaluated in any prior camsirubicin clinical trial."